Peregrine Pharmaceuticals reported $2.74M in Operating Profit for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Profit Change
Agenus AGEN:US $ -44.56M 9.1M
Amgen AMGN:US $ 2176M 324M
AstraZeneca AZN:LN 44.27B 22.58B
Biocryst Pharmaceuticals BCRX:US $ -34.72M 15.24M
Bristol Myers Squibb BMY:US $ 2590M 37M
Celldex Therapeutics CLDX:US $ -36.4M 13.14M
Chemocentryx CCXI:US $ -31.57M 6.66M
Eli Lilly And LLY:US $ 1210.1M 1194.2M
GlaxoSmithKline GSK:LN 108.1B 121.2B
Immunogen IMGN:US $ -61.05M 38.2M
Intrexon XON:US $ -24.16M 6.27M
Karyopharm Therapeutics KPTI:US $ -42908000 8.32M
Macrogenics MGNX:US $ -41808000 24.83M
Mannkind MNKD:US $ -20.45M 0.8M
Merk MRK:US $ 4927M 642M
Minerva Neurosciences NERV:US $ -6.96M 1.02M
Newlink Genetics NLNK:US -7924000 193K
Novartis NOVN:VX 2.23B 624M
Novavax NVAX:US $ -482.96M 692.25M
Peregrine Pharmaceuticals PPHM:US $ 2.74M 1.67M
Repligen RGEN:US $ 63.17M 3.17M
Xencor XNCR:US $ -28M 54.47M